Breaking News Bar

Business News and Information

Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

  • H.C. Wainwright 4th Annual NASH Investor Conference
    Monday, October 5, 2020 – 3:30 pm ET
  • Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
    Monday, October 5, 2020 – 4:45 pm ET

The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at under Events/Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit

Investor Contacts:

Stacey JurchisonAshley R. Robinson
Altimmune, Investor RelationsLifeSci Advisors, LLC
Phone: 410-474-8200617-430-7577

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear